CNBC's Jim Cramer reports on the latest news regarding Moderna.

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Moderna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

Analyst Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report) and decreased the price target to $50.00 from $55.00. Don't Miss our Black Friday Offers: Unlock your ...

Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next ...

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Shares of Moderna Inc. (NASDAQ: MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to ...